Company intelligence / Profile preview

Quantum Genomics

Paris, Ile-de-France, Francequantum-genomics.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 3

Overview

Quantum Genomics developed firibastat (QGC001), a first-in-class brain aminopeptidase A inhibitor for treatment-resistant hypertension. Early-phase trials showed some efficacy in lowering blood pressure in specific patient populations. However, pivotal Phase 3 trials failed to demonstrate efficacy over placebo. As a result, all cardiology development was discontinued by late 2022. The company lacks advanced follow-up assets and has effectively ceased major R&D operations.

Therapeutic areas: HematologyCardiovascularNephrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

firibastat

Partnerships

CNRSINSERMEurofins OptimedPRA Health Sciences

Beyond the preview

Go deeper on Quantum Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantum Genomics.

Explore the full profile